Department of Biomedical Engineering, Graeme Clark Institute, University of Melbourne, Parkville, VIC 3010, Australia.
ACTV Research Group, Melbourne Dental School and The Bio21 Institute of Molecular Science and Biotechnology, The University of Melbourne, Parkville, VIC 3010, Australia.
Acta Biomater. 2023 Mar 1;158:56-79. doi: 10.1016/j.actbio.2023.01.019. Epub 2023 Jan 11.
Fungal infections pose a serious threat to human health and livelihoods. The number and variety of clinically approved antifungal drugs is very limited, and the emergence and rapid spread of resistance to these drugs means the impact of fungal infections will increase in the future unless alternatives are found. Despite the significance and major challenges associated with fungal infections, this topic receives significantly less attention than bacterial infections. A major challenge in the development of fungi-specific drugs is that both fungi and mammalian cells are eukaryotic and have significant overlap in their cellular machinery. This lack of fungi-specific drug targets makes human cells vulnerable to toxic side effects from many antifungal agents. Furthermore, antifungal drug resistance necessitates higher doses of the drugs, leading to significant human toxicity. There is an urgent need for new antifungal agents, specifically those that can limit the emergence of new resistant species. Non-drug nanomaterials have primarily been explored as antibacterial agents in recent years; however, they are also a promising source of new antifungal candidates. Thus, this article reviews current research on the use of inorganic nanoparticles as antifungal agents. We also highlight challenges facing antifungal nanoparticles and discuss possible future research opportunities in this field. STATEMENT OF SIGNIFICANCE: Fungal infections pose a growing threat to human health and livelihood. The rapid spread of resistance to current antifungal drugs has led to an urgent need to develop alternative antifungals. Nanoparticles have many properties that could make them useful antimycotic agents. To the authors' knowledge, there is no published review so far that has comprehensively summarized the current development status of antifungal inorganic nanomaterials, so we decided to fill this gap. In this review, we discussed the state-of-the-art research on antifungal inorganic nanoparticles including metal, metal oxide, transition-metal dichalcogenides, and inorganic non-metallic particle systems. Future directions for the design of inorganic nanoparticles with higher antifungal efficacy and lower toxicity are described as a guide for further development in this important area.
真菌感染对人类健康和生计构成严重威胁。临床上批准的抗真菌药物数量和种类非常有限,而且这些药物的耐药性迅速出现并迅速传播,这意味着除非找到替代品,否则真菌感染的影响将会增加。尽管真菌感染意义重大且面临重大挑战,但与细菌感染相比,人们对其关注度要低得多。开发真菌特异性药物的一个主要挑战是真菌和哺乳动物细胞都是真核生物,它们的细胞机制有很大的重叠。这种缺乏真菌特异性药物靶点的情况使得许多抗真菌药物对人体细胞具有毒性副作用。此外,抗真菌药物耐药性需要更高的药物剂量,从而导致人体毒性显著增加。因此,迫切需要新的抗真菌药物,特别是那些能够限制新耐药物种出现的药物。近年来,纳米材料主要作为抗菌剂在非药物领域得到了广泛的探索;然而,它们也是新的抗真菌候选药物的有前途的来源。因此,本文综述了目前使用无机纳米颗粒作为抗真菌剂的研究进展。我们还强调了抗真菌纳米颗粒面临的挑战,并讨论了该领域未来可能的研究机会。
真菌感染对人类健康和生计构成日益严重的威胁。目前抗真菌药物耐药性的迅速传播导致迫切需要开发替代抗真菌药物。纳米颗粒具有许多特性,使其成为有用的抗真菌剂。据作者所知,目前还没有发表的综述全面总结了抗真菌无机纳米材料的最新发展状况,因此我们决定填补这一空白。在本综述中,我们讨论了包括金属、金属氧化物、过渡金属二卤化物和无机非金属颗粒系统在内的抗真菌无机纳米颗粒的最新研究进展。为了进一步开发这一重要领域,我们还描述了设计具有更高抗真菌功效和更低毒性的无机纳米颗粒的未来方向。